Clinical Trials
42 trialsA Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
AstraZeneca
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
AstraZeneca
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
AstraZeneca
Selumetinib and Olaparib in Solid Tumors
M.D. Anderson Cancer Center
Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies
National Cancer Institute (NCI)
NF113
University of Alabama at Birmingham
BISCAY
AstraZeneca
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
University of Chicago
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies
AstraZeneca
Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
MK-5618-001
Merck Sharp & Dohme LLC
Intermittent Selumetinib for Uveal Melanoma
Columbia University
Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC
Canadian Cancer Trials Group
MK-8353-014
Merck Sharp & Dohme LLC
Selumetinib Paediatric NF1 Japan Study
AstraZeneca
DREAMtherapy
The Christie NHS Foundation Trust
Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
OHSU Knight Cancer Institute
MEKRT
The Christie NHS Foundation Trust
A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum
National Institutes of Health Clinical Center (CC)
A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)
Cancer Research UK
A Study of ARRY-142886 in Patients With Advanced Cancer
Array BioPharma
AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer
National Institutes of Health Clinical Center (CC)
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
AstraZeneca
A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)
Merck Sharp & Dohme LLC
SELECT-3
AstraZeneca
Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer
AstraZeneca
A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers
AstraZeneca
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects
AstraZeneca
ABC-04
University College, London
Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study
AstraZeneca
A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.
AstraZeneca
Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies
National Cancer Institute (NCI)
To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
AstraZeneca
Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers
AstraZeneca
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects
AstraZeneca
To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
AstraZeneca
Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies
AstraZeneca
To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
AstraZeneca
Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK
AstraZeneca
Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
AstraZeneca